血液透析患者SARS-CoV-2免疫应答的持久性及再感染保护
11例抗NP转阴者中8例有特异性T细胞应答。基线血清学阳性者后续6个月PCR确诊感染显著减少。
要点
- 透析患者感染SARS-CoV-2后6个月抗体持久性较好,抗RBD阳性率85.3%。
- 抗体转阴者多数仍存在SARS-CoV-2特异性T细胞应答。
- 基线血清学阳性与后续6个月PCR确诊感染风险降低显著相关。
核心结论
- 接受中心血液透析的患者在SARS-CoV-2感染后6个月可产生持久免疫应答,仅不到3%的患者无体液或细胞免疫证据。
主要发现
- 6个月时71/111(64.0%)抗NP和99/116(85.3%)抗RBD仍血清阳性。
- 保留抗体者6个月后抗NP和抗RBD水平均显著下降。
- 11例基线抗NP阳性者6个月时抗体不可检测,其中8例存在SARS-CoV-2抗原特异性T细胞应答。
- 无论6个月时抗体状态如何,基线SARS-CoV-2血清学阳性者后续6个月PCR确诊感染显著更少。
临床怎么用
- 透析患者感染SARS-CoV-2后6个月内再感染风险较低,但抗体水平随时间下降,需关注免疫保护持续时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with end stage kidney disease receiving in-center hemodialysis (ICHD) have had high rates of SARS-CoV-2 infection. Following infection, patients receiving ICHD frequently develop circulating antibodies to SARS-CoV-2, even with asymptomatic infection. Here, we investigated the durability and functionality of the immune responses to SARS-CoV-2 infection in patients receiving ICHD. Three hundred and fifty-six such patients were longitudinally screened for SARS-CoV-2 antibodies and underwent routine PCR-testing for symptomatic and asymptomatic infection. Patients were regularly screened for nucleocapsid protein (anti-NP) and receptor binding domain (anti-RBD) antibodies, and those who became seronegative at six months were screened for SARS-CoV-2 specific T-cell responses. One hundred and twenty-nine (36.2%) patients had detectable antibody to anti-NP at time zero, of whom 127 also had detectable anti-RBD. Significantly, at six months, 71/111 (64.0%) and 99/116 (85.3%) remained anti-NP and anti-RBD seropositive, respectively. For patients who retained antibody, both anti-NP and anti-RBD levels were reduced significantly after six months. Eleven patients who were anti-NP seropositive at time zero, had no detectable antibody at six months; of whom eight were found to have SARS-CoV-2 antigen specific T cell responses. Independent of antibody status at six months, patients with baseline positive SARS-CoV-2 serology were significantly less likely to have PCR confirmed infection over the following six months. Thus, patients receiving ICHD mount durable immune responses six months post SARS-CoV-2 infection, with fewer than 3% of patients showing no evidence of humoral or cellular immunity.
引用
- Clarke CL, Prendecki M, Dhutia A, et al. Longevity of SARS-CoV-2 immune responses in hemodialysis patients and protection against reinfection. Kidney Int. 2021. PMID: 33774082. doi:10.1016/j.kint.2021.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。